The collaboration aims to uncover clinically actionable patient subpopulations and biomarker-driven treatment insights from a landmark precision-oncology trialTORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced a strategic research collaboration with Fondazion ...

Core Insights - NetraMark Holdings Inc. has demonstrated the potential of its explainable AI platform, NetraAI, to identify clinically meaningful responder subgroups in the A4 trial for Alzheimer's disease, which could enhance precision medicine strategies in future clinical trials [1][4][10] Group 1: Findings from the A4 Trial - The A4 trial initially showed no significant overall benefit for solanezumab, but NetraAI identified two distinct patient subgroups with meaningful treatment effects compared to placebo [4][7] - Key characteristics of these subgroups include higher regional brain volume and stronger baseline cognitive performance, with effect sizes reaching Cohen's d up to 1.52 [7] Group 2: Implications for Drug Development - The findings highlight the challenge of patient heterogeneity in Alzheimer's clinical trials, which can obscure meaningful drug responses [5][10] - NetraAI's ability to define subgroups based on a small number of baseline variables could support precision enrichment strategies, improving trial design and potentially reducing development risks and costs [8][9] Group 3: Technological Advancements - NetraAI employs a unique methodology that separates small datasets into explainable and unexplainable subsets, enhancing the likelihood of clinical trial success by avoiding overfitting [11] - The technology aligns with the industry's shift towards understanding which patients are most likely to benefit from therapies, thereby reshaping clinical trial designs [10][12]

Core Insights - NetraMark Holdings Inc. has signed a new contract with a leading global biopharmaceutical company to analyze data from a Phase 2 clinical trial for depression, further extending its portfolio of AI-driven projects in psychiatric and neurological disorders [1][4] Group 1: Company Developments - The agreement allows NetraMark to utilize its proprietary AI methodology to analyze multi-dimensional clinical data, aiming to identify patient subpopulations likely to benefit from treatment and inform future study designs [3][4] - NetraMark's NetraAI platform employs a dynamical systems framework that effectively handles complex, small clinical datasets, enabling the stratification of high-effect-size patient subpopulations [5][7] - The company focuses on developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions specifically for the pharmaceutical industry, utilizing a novel topology-based algorithm to parse patient data into meaningful subsets [7] Group 2: Industry Context - The collaboration highlights the increasing demand from pharmaceutical companies for better understanding of patient heterogeneity in clinical trials, which is crucial for optimizing dosing decisions and improving study success rates [2][3] - NetraAI's unique focus mechanisms differentiate it from other AI methods by preventing overfitting and enhancing the accuracy of insights derived from clinical data, potentially increasing the likelihood of clinical trial success [6]

Core Viewpoint - NetraMark Holdings Inc. successfully closed the second tranche of its non-brokered private placement, raising a total of $3.5 million through the issuance of 3.5 million units at $1.00 per unit, with plans to use the proceeds for working capital and general corporate purposes [1][4]. Group 1: Private Placement Details - The second tranche involved the issuance of 390,000 units at a price of $1.00 per unit, resulting in gross proceeds of $390,000 [1]. - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of an additional common share at an exercise price of $1.35 for two years [2]. - The total number of common shares outstanding after the second tranche is 92,223,699 [4]. Group 2: Regulatory and Insider Participation - The securities issued are subject to a four-month hold period, expiring on June 19, 2026, in accordance with Canadian securities laws [3]. - An insider participated in the second tranche, subscribing for 232,500 units, which is classified as a related party transaction [5]. - The company is exempt from formal valuation and minority shareholder approval requirements due to the transaction's size relative to its market capitalization [5]. Group 3: Company Overview and Technology - NetraMark is focused on developing AI and machine learning solutions for the pharmaceutical industry, utilizing a unique topology-based algorithm to analyze patient data [8][9]. - The company's technology allows for the segmentation of small datasets into explainable and unexplainable subsets, enhancing the accuracy of clinical trial insights [7].

Core Viewpoint - NetraMark Holdings Inc. is uplisting to the Toronto Stock Exchange (TSX) from the Canadian Securities Exchange (CSE), which is expected to enhance its access to institutional investors and raise its profile in the capital markets [1][4]. Group 1: Uplisting Details - The common shares of NetraMark will be voluntarily delisted from the CSE effective February 17, 2026, and will commence trading on the TSX under the symbol "AIAI" on February 18, 2026 [1][2]. - The company will remain a "reporting issuer" under applicable Canadian securities laws during the transition from CSE to TSX [2]. Group 2: Company Strategy and Technology - The uplisting is seen as a significant milestone that reflects NetraMark's operational development and strengthens its positioning within capital markets as it advances the commercial adoption of its AI-powered platform, NetraAI [3][4]. - NetraAI is designed to separate small datasets into explainable and unexplainable subsets, potentially increasing the likelihood of clinical trial success by avoiding overfitting [5]. - The company focuses on developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions for the pharmaceutical industry, utilizing a novel topology-based algorithm to accurately segment diseases and classify patients [6].

Core Viewpoint - NetraMark Holdings Inc. has successfully closed the first tranche of a non-brokered private placement, raising gross proceeds of $3,110,000, which will be utilized for working capital and general corporate purposes [1][4]. Group 1: Private Placement Details - The first tranche involved the issuance of 3,110,000 units at a price of $1.00 per unit, with each unit consisting of one common share and one-half of a common share purchase warrant [2]. - Each warrant allows the holder to acquire an additional common share at an exercise price of $1.35 for a period of two years from the closing date [2]. - The securities issued are subject to a hold period expiring on May 28, 2026, as per applicable securities laws [3]. Group 2: Future Tranche and Financial Commitments - The company has received commitments for the second and final tranche of the private placement, expected to close soon for additional gross proceeds of $390,000 [4]. - Following the first tranche, there are now 91,778,520 common shares of NetraMark issued and outstanding [3]. Group 3: Insider Participation - Certain insiders participated in the first tranche, subscribing for a total of 2,060,000 units, which is classified as a related party transaction [5]. - The company is exempt from formal valuation and minority shareholder approval requirements due to the nature of the transaction and its market capitalization [5]. Group 4: Company Overview - NetraMark is focused on developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions for the pharmaceutical industry, utilizing a novel topology-based algorithm to analyze patient data [8]. - The company's AI technology, NetraAI, is designed to improve clinical trial success rates by effectively segmenting patient data into explainable and unexplainable subsets, addressing issues of overfitting common in other AI methods [7].

Core Viewpoint - NetraMark Holdings Inc. is conducting a non-brokered private placement to raise up to $3,500,000 CDN through the issuance of 3,500,000 units at a price of $1.00 per unit, aimed at advancing its AI-powered clinical trial analytics platform and supporting biopharmaceutical engagements [1][4]. Group 1: Offering Details - The offering consists of units that include one common share and one-half of a common share purchase warrant, with the whole warrant allowing the purchase of an additional share at $1.35 for two years [2]. - The offering will be completed under exemptions from prospectus requirements, with a statutory hold period of four months and one day for the issued shares and warrants [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general working capital and corporate purposes, specifically for the advancement and commercialization of the NetraAI platform and support for ongoing and prospective biopharmaceutical engagements [4]. Group 3: Company Overview - NetraMark focuses on developing Generative AI and Machine Learning solutions for the pharmaceutical industry, utilizing a unique topology-based algorithm to analyze patient data effectively [7]. - The NetraAI platform is designed to separate small datasets into explainable and unexplainable subsets, enhancing the accuracy of clinical trial insights and reducing the risk of overfitting [6].

Core Insights - NetraMark Holdings Inc. has made significant progress in commercial execution, regulatory engagement, and scientific validation, strengthening its growth trajectory in AI-driven clinical trial optimization [1][2] Group 1: Contract Backlog and Financial Outlook - The contract backlog for NetraMark increased to approximately C$2.5 million, driven by new project commitments and commercial momentum, with a target of reaching C$8–$10 million by mid-2026 [2][4] - The company is experiencing growing commercial traction and expanding channel partnerships, which support its financial outlook [4] Group 2: Regulatory Engagement - NetraMark completed a Critical Path Innovation Meeting (CPIM) with the FDA, receiving feedback on its NetraAI platform and its application in clinical trial design [2] - The FDA discussed considerations for identifying responder-enriched subgroups while maintaining control of Type I error, aligning with FDA enrichment guidance [2] Group 3: Scientific Validation - A scientific study on NetraAI was accepted for publication in npj Digital Medicine, demonstrating its ability to identify clinically meaningful subgroups in a Phase II depression trial [2] - The acceptance by a high-impact journal provides third-party validation of NetraMark's scientific approach [2] Group 4: Strategic Collaborations - NetraMark secured an Ontario Research Fund – Research Excellence Award in collaboration with the Centre for Addiction and Mental Health (CAMH), focusing on analyzing genetic and epigenetic data in psychiatric disorders [2] - This collaboration aims to enhance NetraAI's capabilities in identifying explainable patient subpopulations [2]

Core Insights - NetraMark Holdings Inc. has been awarded the Ontario Research Fund - Research Excellence Award in collaboration with the Centre for Addiction and Mental Health (CAMH) for their innovative partnership in advancing research and technology in mental health [1][2]. Group 1: Collaboration and Research Focus - The collaboration will utilize NetraAI, a machine learning platform, to analyze genetic and epigenetic data from studies on schizophrenia and major depressive disorder [2][3]. - The initiative aims to identify explainable patient subpopulations to clarify biological subtypes in psychiatric disorders, supporting next-generation precision treatment strategies [3]. Group 2: Technological Advancements - NetraAI is designed to separate small datasets into explainable and unexplainable subsets, enhancing the accuracy of insights derived from clinical trials [6]. - The platform's unique focus mechanisms aim to reduce the risk of overfitting, which can lead to inaccurate insights and improve the chances of clinical trial success [6]. Group 3: Impact on Clinical Trials - The collaboration is expected to enhance NetraAI's capabilities to serve pharmaceutical sponsors, ultimately improving clinical trial outcomes in the psychiatric space [3][4]. - The research will also evaluate additional datasets from the Ontario Health Insurance Plan (OHIP) to analyze cost-effectiveness and the broader health-system impact of personalized patient care [4]. Group 4: Institutional Background - CAMH is recognized as Canada's largest mental health and addiction teaching hospital, combining clinical care, research, education, and policy development to transform the lives of individuals affected by mental illness [5]. - The partnership with CAMH allows NetraMark to leverage extensive genomic and clinical datasets to explore genetic influences on treatment responses [4]. Group 5: Company Overview - NetraMark focuses on developing Generative Artificial Intelligence and Machine Learning solutions specifically for the pharmaceutical industry, utilizing a novel algorithm to parse patient data effectively [7]. - The company's approach enables accurate segmentation of diseases and classification of patients based on treatment sensitivity and efficacy [7].

Core Insights - NetraMark Holdings Inc. has completed its Critical Path Innovation Meeting (CPIM) with the FDA, discussing its AI platform, NetraAI, and its potential in clinical trial design [1][2][4] - The FDA provided feedback on NetraAI's explainable AI/ML capabilities and suggested exploring the Model-Informed Drug Development (MIDD) Paired Meeting Program for further regulatory dialogue [2][3][4] Company Overview - NetraMark is focused on developing AI and machine learning solutions for the pharmaceutical industry, utilizing a novel algorithm to analyze patient datasets effectively [6] - The company's platform, NetraAI, is designed to identify biological and clinical signatures in small datasets, enhancing the likelihood of clinical trial success [2][5] Regulatory Engagement - The CPIM with the FDA is a significant step for NetraMark, providing insights into regulatory considerations for AI in clinical development [4] - The FDA's engagement reinforces the importance of explainability and scientific rigor in AI applications for drug development [2][3] Technical Differentiation - NetraAI employs unique focus mechanisms to separate explainable and unexplainable subsets of data, addressing challenges like overfitting that can compromise trial outcomes [5] - The platform's approach allows for targeted inclusion/exclusion criteria and pre-specified stratification in trial designs, potentially improving statistical power and reducing trial risks [3][4]